It has been shown by REVIVE II study to confer early additional benefit in addition to standard therapy in ADHF patients, but it is yet to be approved in the USA due to a possible trend towards increased mortality [ 2 ]. 5) Vasopressors/ B -Blockers/ACEIs Use of vasopressors is mostly for HFpEF patients with severe ADHF and hypotension or signs of shock.
← all excerpts
A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure.
1
—
—